Search - tctmd.com

Displaying 1 - 20 of 160

Sort: Relevancy | Date

Loberamisal Scores a Rare Win for Stroke Neuroprotection

News Conference News ISC 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

February 12, 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

News Conference News ISC 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

February 11, 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

February 09, 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

February 06, 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

News Conference News ISC 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

February 05, 2026

TCTMD’s Top 10 Most Popular Stories for January 2026

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2026

February 02, 2026

AHA/ASA Release New Comprehensive Acute Ischemic Stroke Guideline

News Daily News

AHA/ASA Release New Comprehensive Acute Ischemic Stroke Guideline

January 29, 2026

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

September 03, 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

August 31, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

Simple, Phone-Based Strategy Improves BP Control in Stroke Survivors

News Conference News ESOC 2025

Simple, Phone-Based Strategy Improves BP Control in Stroke Survivors

June 02, 2025

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

News Conference News ESOC 2025

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

May 28, 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.